Table 2 Clinical outcomes among the trials included
Author | Antibiotic regimen | Mortality rate, % (n/N) | Clinical cure, % (n/N) | Microbiological success, % (n/N) |
|---|---|---|---|---|
Titov et al | Imipenem/Cilastatin/Relebactam | 15.9 (42/264) | 61 (161/264) | 67.9 (146/215) |
Piperacillin/Tazobactam | 21.4 (57/267) | 55.8 (149/267) | 61.9 (135/218) | |
Zanetti et al | Cefepime | 25.9 (28/108) | 70.4 (76/108) | 61 (47/77) |
Imipenem/Cilastatin | 18.8 (19/101) | 74.3 (75/101) | 53.5 (38/71) | |
Wunderink et al | Cefiderocol | 20.7 (30/145) | 64.8 (94/145) | 40.7 (59/145) |
Meropenem | 20.4 (30/147) | 66.7 (98/147) | 41.5 (61/147) | |
Torres et al | Ceftazidime/Avibactam | 8.2 (29/356) | 51.4 (132/257) | 55.6 (95/171) |
Meropenem | 6.8 (25/370) | 48.5 (131/270) | 64.1 (118/184) | |
Schmitt et al | Piperacillin/Tazobactam | 15.9 (17/107) | 59.8 (64/107) | 34.6 (37/107) |
Imipenem/Cilastatin | 10 (11/110) | 66.4 (73/110) | 46.4 (51/110) | |
Chastre et al | Doripenem | 10.8 (27/249) | 68.3 (86/126) | 69 (80/116) |
Imipenem/Cilastatin | 9.5 (24/252) | 64.8 (79/122) | 64.5 (71/110) | |
Kollef et al | Doripenem | 20.9 (24/115) | 45.6 (36/79) | 45.6 (36/79) |
Imipenem/Cilastatin | 14.3 (16/112) | 56.8 (50/88) | 56.8 (50/88) | |
Kollef et al | Ceftolozane/Tazobactam | 24 (87/362) | 54.4 (197/362) | 53.3 (193/362) |
Meropenem | 25.3 (92/364) | 53.3 (194/364) | 46.2 (168/364) | |
Cisneros et al | IV Colistin | 22.5 (27/120) | 68.3 (82/120) | 56.1 (46/82) |
Meropenem | 21.4 (24/112) | 72.3 (81/112) | 51.2 (42/82) | |
Réa-Neto et al | Doripenem | 13.8 (30/217) | 81.3 (109/134) | 84.8 (84/99) |
Piperacillin/Tazobactam | 14.6 (31/212) | 79.8 (95/119) | 80.6 (83/103) | |
Yamamato et al | Piperacillin/Tazobactam | 2.9 (1/34) | 75.9 (22/29) | 84.2 (16/19) |
Meropenem | 9.1 (3/33) | 64.3 (18/28) | 94.4 (17/18) | |
Lerma et al | Meropenem | 23.2 (16/69) | 56.5 (39/69) | 55.1 (38/69) |
Ceftazidime | 28.2 (20/71) | 40.8 (29/71) | 33.8 (24/71) | |
Torres et al | Ciprofloxacin | 19.5 (8/41) | 70.7 (29/41) | 48.8 (20/41) |
Imipenem/Cilastatin | 11.8 (4/34) | 79.4 (27/34) | 50 (17/34) | |
Abdelsalam et al | Colistin (IV) | 43.3 (13/30) | 56.7 (17/30) | NA |
Meropenem + Colistin (AS) | 16.7 (5/30) | 83.3 (25/30) | NA | |
Alvarez-Lerma et al | Piperacillin/Tazobactam | 30.7 (27/88) | 50 (44/88) | 62 (31/50) |
Ceftazidime | 22.2 (8/36) | 44.4 (16/36) | 65 (13/20) | |
Joshi et al | Piperacillin/Tazobactam | 10.4 (23/222) | 54.5 (121/222) | 72.3 (112/155) |
Imipenem/Cilastatin | 7.9 (17/215) | 51.6 (111/215) | 76.9 (93/121) |